BPC-157 Quality Documents: What a Certificate of Analysis Can—and Can’t—Tell You
Research reviewed November 2, 2026
When people ask about the quality of a compounded peptide, they may hear that a “certificate of analysis” is available. That document can be useful, but its meaning depends on what was tested, which material and batch it covers, and who performed or reviewed the testing.
A CoA is not a universal certification of a finished medication. It does not, by itself, prove that a product is FDA-approved, clinically effective, safe for a particular person, or suitable for a particular use. FDA explains that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing in its compounding questions and answers.
Start by checking what the document covers
Before drawing conclusions from a CoA, identify the material it describes. Does it cover a raw ingredient, an intermediate, or the finished compounded preparation? Is there a lot or batch number, and does that number match the material or product being discussed? Is the document tied to a named manufacturer or testing laboratory?
These questions matter because results for one material or batch do not automatically establish the characteristics of another. A document that reports a test result for a bulk ingredient should not be described as a test of every finished dosage form made with that ingredient.
FDA’s July 2026 Pharmacy Compounding Advisory Committee materials show that the agency’s review of BPC-157-related bulk drug substances includes concerns about limited safety information and complexities involving peptide-related impurities and active pharmaceutical ingredient characterization. The committee’s discussion and recommendations are part of an advisory process; they are not themselves final FDA approval actions.
Ask what the tests actually establish
A document may list tests for identity, purity, potency or content, impurities, or other characteristics. The test name alone is not enough to interpret the result. Readers should check the method, acceptance criteria, reported result, and whether the test was performed on the same material and batch being discussed.
A reported identity result, for example, addresses a different question from a clinical study. A purity result does not show that a substance improves a health outcome. And a test of an ingredient does not automatically establish the quality of a finished compounded drug.
The HHS document published October 30 is a draft enforcement-discretion policy, not a final FDA rule or approval. It names BPC-157 acetate and describes conditions that include substance identity, sourcing, documentation, and reporting. The Federal Register notice and HHS policy text should be read directly for those conditions. The draft does not make every certificate or supplier statement equivalent, nor does it make a quality document proof of clinical benefit.
Keep quality, regulatory status, and evidence separate
Three questions are often blended together:
- What does the document say was tested? This is a question about the scope and results of testing.
- What regulatory framework applies? This requires reviewing current federal policy and applicable state requirements.
- What evidence supports a health claim? This requires human clinical evidence relevant to the specific use and formulation.
A 2026 systematic review of human BPC-157 research found only three small studies, with 30 participants in total, within the review’s stated scope. The authors rated the studies’ methodological quality as poor and the overall certainty of evidence as very low. A quality document cannot fill that clinical evidence gap.
The ClinicalTrials.gov record for a Phase II hamstring-strain study currently lists the study as recruiting. A recruiting trial means research is underway; it does not provide completed results or establish effectiveness.
Oral products raise a formulation-specific question
For oral products, testing an ingredient’s identity or purity does not answer whether a specific formulation achieves adequate bioavailability in humans. The HHS draft policy expressly expects documentation addressing adequate human oral bioavailability for the specific formulation. See the policy’s text.
That condition should not be inferred from animal findings, another dosage form, or a document that only describes ingredient quality. Bioavailability and clinical benefit are also different questions: evidence that a substance is absorbed would not, on its own, show that it improves a health outcome.
State requirements remain relevant
Federal policy does not replace state pharmacy laws and practice requirements. Pharmacies, prescribers, and healthcare organizations should consult the rules applicable to their location and the patient’s location. For Texas, the State Board of Pharmacy’s laws and rules page is a source for current state requirements.
A document’s existence does not establish that a particular pharmacy, prescriber, product, or dispensing arrangement satisfies every applicable requirement. Those determinations depend on the facts and current law.
Questions to ask when reviewing a CoA
For general education, a careful review can ask:
- What specific material and batch does the document identify?
- Who issued it, and who performed the testing?
- Which methods and acceptance criteria are shown?
- Which results are reported, and what do those tests establish?
- Is it a raw-material document or does it cover a finished preparation?
- For an oral formulation, is there separate documentation about adequate bioavailability in humans for that specific formulation?
- What current federal and state requirements should the pharmacy and prescriber verify?
These questions help clarify what a document can support. They are not a substitute for regulatory review or individualized medical advice.
The takeaway
A certificate of analysis can provide batch-specific information about the tests it reports. Its value depends on its scope, methods, source, and connection to the material at issue. It does not establish FDA approval, clinical effectiveness, or suitability for a particular person.
The October 30 HHS document remains a draft enforcement-discretion policy. It is distinct from FDA approval, a final addition to the 503A bulks list, and clinical evidence. For general information, see Scripx compounding services or contact the Scripx pharmacy team. These are general pharmacy links and do not identify a BPC-157 product or confirm its availability.
This article is for general education and is not medical or legal advice. It does not recommend starting, stopping, dosing, or purchasing BPC-157. Compounded drugs are not FDA-approved. Policy and requirements can change; consult current primary sources and qualified professionals.
FAQ
Does a certificate of analysis prove a compounded product is effective?
No. It reports results for the tests it covers. Clinical effectiveness requires relevant clinical evidence.
Does a CoA for an ingredient prove the finished compounded product was tested?
Not necessarily. Check whether the document identifies raw material, an intermediate, or a finished preparation, and confirm the batch or lot.
Does a purity result prove safety?
No. A reported purity result is limited to the test, method, material, and criteria described. It does not establish safety for every route or patient.
Does oral bioavailability documentation prove that BPC-157 works?
No. The draft policy expects documentation of adequate human bioavailability for the specific oral formulation. Bioavailability does not itself establish clinical benefit.
Is the October 30 HHS document a final FDA approval?
No. It is a draft HHS enforcement-discretion policy. It is not FDA approval or a final rule adding BPC-157 to the 503A bulks list.